An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
InterCure (INCR) expects to launch products in Germany following the passing of the 'CannG' Cannabis Act, which will make prescribing medical cannabis easier and more cost-effective. The company anticipates significant growth in the German medical cannabis market.
Positive
None.
Negative
None.
Insights
The recent legislative change in Germany, known as the 'CannG' Cannabis Act, is a pivotal moment for the medical cannabis industry. It is expected to broaden the market by simplifying the prescription process and reducing costs. This, in turn, could lead to increased demand for medical cannabis products. Companies like InterCure, which are poised to enter the German market, could benefit significantly from this expanded customer base. However, it's essential to monitor how this change will affect the competitive landscape, as new and existing players may adjust their strategies to capitalize on the growing market. The impact on InterCure's stock will largely depend on their ability to effectively penetrate the market and maintain a competitive edge.
The deregulation of medical cannabis in Germany represents a major shift in healthcare policy that could serve as a model for other countries considering similar reforms. The removal of cannabis from the list of prohibited substances under the German Narcotics Act eases the burden on healthcare providers and patients, potentially improving the quality of life for those with chronic conditions. It's important to consider the long-term implications of such a policy shift, including the need for robust regulatory frameworks to ensure product safety and consistency. The success of medical cannabis companies in this new environment will hinge on their ability to navigate these regulations while meeting the increased demand.
Investors should pay attention to the financial implications of Germany's cannabis reform for companies like InterCure. The anticipation of entering the German market may already be factored into InterCure's current valuation, but actual performance post-launch will be the true test. Key financial metrics to watch include revenue growth, market share and profit margins post-expansion. Additionally, the company's ability to scale operations and manage supply chain logistics in a new market environment will be critical for long-term profitability. While the reform presents a significant opportunity, it also comes with the risk of increased operational costs and potential price competition as the market matures.
InterCure provides an update following recent Cannabis Reform in Germany
Expects to launch its first products in Germany in the coming months
The Company continues to closely watch developments surrounding Cannabis rescheduling in the U.S.
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--
InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the “CannG” Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.
While the Cannabis Act deals with all types of cannabis, it is poised to have a uniquely significant impact on the medical cannabis sector. By excising cannabis from the list of prohibited substances in the German Narcotics Act, the reform makes prescribing medical cannabis to patients substantially easier and more cost-effective for doctors at greater scale and not only as a last resort. Thus, this reform is set to dismantle major barriers that have historically hindered patient access to cannabis-based treatments. This sets the stage for expected significant expansion of the medical cannabis market in Germany.
Alexander Rabinovitch, CEO of InterCure, expressed his excitement about the legislative changes in Germany, stating, "We are thrilled by the recent reform passed in Germany and are optimistic about the global shift that is taking place. As a leader in pharmaceutical Cannabis, we are closely watching these developments including the potential rescheduling of Cannabis in the United States, and plan to advance our global footprint, expecting to launch our products in Germany in the coming months. The strong foundation we have built over the past 15 years serves us today as we continuously execute our mission of providing high-quality, pharma-grade medical cannabis products to patients around the world."
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
Forward‐Looking Statements
This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the security events in Israel, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic, the impact of the war in Israel and the war in Ukraine and the conditions of the markets generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” in InterCure’s Annual Information Form dated March 31, 2023, which is available on SEDAR at www.sedar.com, and under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form 20-F, filed with the Securities Exchange Commission on May 1, 2023. InterCure undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
When does InterCure expect to launch its products in Germany?
InterCure expects to launch its products in Germany in the coming months following the passing of the 'CannG' Cannabis Act.
What is the expected impact of the 'CannG' Cannabis Act on medical cannabis sector in Germany?
The 'CannG' Cannabis Act is expected to make prescribing medical cannabis easier and more cost-effective for doctors, leading to greater patient access to cannabis-based treatments.
